Navigation Links
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Date:9/21/2007

val falls to approximately 15%.(4)

Non-Small Cell Lung Cancer is the most common type of Lung Cancer, making up nearly 80% of all cases. This type of Lung Cancer grows and spreads more slowly than small cell lung cancer. Non-small cell lung cancer is divided into three different subcategories. Squamous cell carcinoma originates in the thin, flat cells that line the passages of the respiratory tract. Adenocarcinoma begins in the cells that form the lining of the lungs. Large cell carcinomas make up a group of cancers that look large and abnormal under a microscope.

About vandetanib (ZACTIMA)

Vandetanib is being studied as a multitargeted compound, directed to the inhibition of key cell signaling pathways involved in tumor growth and spread. Tumor cells are targeted through inhibition of epidermal growth factor receptor (EGFR) and REarranged during Transfection (RET) tyrosine kinases, while tumor blood supply is targeted through inhibition of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. RET tyrosine kinase activity is an important growth driver in certain lung tumors.

Other studies currently recruiting within the NSCLC Phase III clinical development program are:

-- ZEAL (ZACTIMA Efficacy (or Evaluation) with Alimta in Lung cancer)

-- ZEN (ZACTIMA efficacy in EGFR Failures in Non-small cell lung cancer)

-- ZEST (ZACTIMA Efficacy when Studied versus Tarceva)

The primary endpoints for these studies are PFS and OS.

ZACTIMA(TM) is a trademark of the AstraZeneca group of companies.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncolo
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 DST Health Solutions, LLC (DSTHS), a ... plans, integrated delivery systems, and health care providers, has ... Service (MDMS) has jumped significantly. A ... pricing of medical prescription drug claims, MDMS ... medical drug claims processes. As specialty drug demand grows ...
(Date:6/19/2013)... , June 19, 2013   Life Technologies ... a licensing agreement granting Suzhou Ribo Life Sciences ... siRNA therapeutics in China ... formulate proprietary siRNA molecules in combination with Invivofectamine® ... address human diseases with high unmet medical need ...
(Date:6/19/2013)... 19, 2013  It may seem like an odd pairing: ... cancer. But these were two of the most talked about ... Annual Meeting & Expo that just convened in ... focus by some of the top internal medicine experts in ... new research that can not only save lives, but help ...
Breaking Medicine Technology:Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4
... Calif., Dec. 14, 2010 Samplify Systems, Inc., ... for the ultrasound market, is pleased to announce ... imaging has won Electronic Design Magazine,s ... medical category.  Details of Samplify,s AutoFocus™ beamforming technology ...
... VIVUS, Inc. (Nasdaq: VVUS ) today announced ... secure regulatory approval for QNEXA® in the U.S., submitted a ... to address items in the FDA,s Complete Response Letter (CRL), ... the Endocrine and Metabolic Division of the FDA has granted ...
Cached Medicine Technology:Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 2VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 3
(Date:6/19/2013)... (June 19, 2013) The results of three important ... Neurosurgery , official journal of the Congress ... by Lippincott Williams & Wilkins , a part ... indicates that continuous "machine learning" using artificial neural networks ... patients with advanced brain cancers. Another study in the ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... Casual, no-strings sexual encounters are increasingly common ... likely than others to "hook up"? A new ... for Behavioral and Preventive Medicine, published online by ... there are certain factors and behaviors associated with ... , "Given the potential for negative emotional and ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Effective Environmental Services ... of new websites. These online links are devoted to a ... Tank cleaner, Organic Odor Control Mold Magician and others. , ... fish and animals in the water as well as living ... sludge buildup that can accumulate at the bottom of a ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 North ... announced organizational changes to advance development of its ... said, “To support the advanced development of our ... changes to the Company’s management structure and engaged ... The Company announced that Michael Galiger will serve ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Why are some college students more likely to 'hook up'? 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3
... September 10 IDenta Corp. (OTC:,IDTA.PK) announced today ... a recent French television news broadcast. TF1, the ... 7, 2007 during an evening,news program (at 8 ... Police,using the IDenta cocaine detection kit to test ...
... N.Y., Sept. 10 Physicians and patients,of ... benefit from an,enhanced partnership between Physicians Practice ... more than 7,000 physicians in Brooklyn,and Staten ... thereby,improving patient care. (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/NETU093LOGO ...
... Sept. 10 Mylan Laboratories Inc.,(NYSE: MYL ... received,tentative approval from the U.S. Food and Drug ... for Topiramate Capsules, 15 mg and,25 mg. ... McNeil,Pharmaceuticals, Topamax(R) Sprinkle Capsules which had U.S. sales ...
... Sept. 10 Marianjoy Medical,Group is pleased to ... medicine and rehabilitation practice which is based in,Wheaton, ... of Rush Oak Park Hospital,s,Rehabilitation Program and Services. ... medicine, and his medical practice addresses the,medically complex ...
... 10 Maxim Health Systems today,announced it will launch ... Maxim will provide flu shots nationwide through more,than 24,000 ... helps users find a convenient location for,vaccination clinics ... the site to,obtain times and locations for clinics. ...
... N.J., Sept. 10 Companies spend huge sums on,consultants ... and,profitable. But too often, advertising and marketing is left ... that requested an unbiased second opinion,for their advertising and ... and marketing consultancy. Why is advertising neglected? Anthony ...
Cached Medicine News:Health News:Drug Detection Kits Manufactured By IDenta Corp. Shown During French Television Broadcast (at TF1) - Product Aids French Police In Bust of 600 Kilograms Of Cocaine 2Health News:Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors 2Health News:Dr. Mahesh Ramachandran Joins Marianjoy Medical Group 2Health News:Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide 2Health News:Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide 3Health News:CEOs Need an Advertising Check Up or Second Opinion 2
... Compact Sigma is designed to easily ... precise mechanical coupling eliminates clumsy time ... performed as well. Dorniers patented isocentric ... ,Positioning is simple using the Dornier ...
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only....
... ideally suited for high volume stone centers. This ... and an advanced urological table. With the Dornier ... provides successful treatments for a full range of ... URS and PCN procedures are easy. One of ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
Medicine Products: